DNA Liste de produits
You Have Viewed 0 Of 0 Results
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| BI-836858 | BI-836858 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| CART-33 (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details | |
| Lintuzumab Ac-225 (Actinium Pharmaceuticals) | 225Ac-HuM-195; HuM195-Ac-225; AC225-MOAB-M195 | Phase 2 Clinical | Pdl Biopharma Inc | Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| VBP-301 | VBP301; VBP-301 | Phase 2 Clinical | Vor Biopharma Inc | Leukemia, Myeloid, Acute | Details |
| VBP-101 | VBP101; VBP-101 | Phase 2 Clinical | Vor Biopharma Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| VCAR-33 (Vor Biopharma) | VCAR-33; VCAR33 | Phase 2 Clinical | Vor Biopharma Inc | Leukemia, Myeloid, Acute | Details |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| CD33 CAR T Cells(Beijing Boren Hospital) | Phase 2 Clinical | Beijing Gao Boren Hospital Co Ltd | Leukemia; Neoplasms; Leukemia, Myeloid, Acute | Details | |
| Emerfetamab | AMG-673; AMG673 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| ICG-136 | ICG-136; 123b-33bcCAR | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Leukemia, Myeloid, Acute | Details |
| Vixtimotamab | T-564; AMV-564 | Phase 1 Clinical | Amphivena Therapeutics Inc | Solid tumours; Myelodysplastic Syndromes | Details |
| AL-003 | AL-003 | Phase 1 Clinical | Abbvie Inc, Alector Inc | Alzheimer Disease | Details |
| PRGN-3006 | PRGN-3006 | Phase 1 Clinical | Precigen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| IM73 chimeric antigen receptor T cell therapy | IM-73-CAR-T | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Leukemia, Myeloid, Acute | Details |
| ORM-6151 | ORM-6151 | Phase 1 Clinical | Orum Therapeutics Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| SENTI-202 | SENTI-202 | Phase 1 Clinical | Senti Biosciences Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| JNJ-67571244 | JNJ-67571244; JNJ-67371244; JNJ-1244 | Phase 1 Clinical | Johnson & Johnson | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| CD33-NKE | CD33-NKE; CD33 NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Leukemia, Myeloid, Acute | Details |
| Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Leukemia, Myeloid, Acute | Details | |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd | Neoplasm, Residual; Leukemia, Myeloid, Acute | Details | |
| CD33 CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co Ltd | Neoplasm, Residual; Leukemia, Myeloid, Acute | Details | |
| IMGN-779 | IMGN-779 | Phase 1 Clinical | Immunogen Inc | Leukemia, Myeloid, Acute | Details |
| Eluvixtamab | MT-114; AMG-330 | Phase 1 Clinical | Amgen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| IBR-733 | IBR-733; IBR733 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details |
| CD33 CAR-T Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| CLL1+CD33 CAR-T(Zhejiang University) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| anti-CD33 CAR T cells therapy（iCell Gene Therapeutics） | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL1 CAR-NK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Leukemia, Myeloid, Acute | Details | |
| Lintuzumab Ac-225/Venetoclax | Phase 1 Clinical | Actinium Pharmaceuticals Inc | Leukemia, Promyelocytic, Acute | Details | |
| DXC-007(Hangzhou Dac Biotech Company) | DXC-007 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Leukemia; Leukemia, Myeloid, Acute | Details |
| Lintuzumab-gelonin conjugate | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details | |
| Anti-CD33/CLL-1 CAR-T (Legend) | Phase 1 Clinical | Legend Biotech Corp | Leukemia, Promyelocytic, Acute | Details | |
| Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) | Phase 1 Clinical | University Of California San Diego | Leukemia, Myeloid, Acute | Details | |
| Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Gemtuzumab ozogamicin | CMA-676; CDP-771; WAY-CMA-676; CL-555201; hP67.6-calicheamicin | Approved | Ucb Sa, Pfizer Inc | Mylotarg | Japan | Leukemia, Myeloid, Acute | Pfizer Inc | 2008-01-18 | Leukemia; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Leukemia, Lymphocytic, Chronic, B-Cell | Details |